Trial Profile
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jun 2023
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Lenalidomide (Primary)
- Indications Smoldering multiple myeloma
- Focus Therapeutic Use
- 15 May 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results assessing immune biomarkers of progression performing single-cell RNA- and T-cell receptor sequencing using samples from 34 patients with high-risk smoldering multiple myeloma from this trial presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 14 Nov 2022 Results assessing Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma published in the Cancer Cell